title: Infant baboons infected with respiratory syncytial virus develop clinical and pathological changes that parallel those of human infants.
abstract: Respiratory syncytial virus (RSV) infection of the lower respiratory tract is the leading cause of respiratory failure among infants in the United States of America and annually results in >300,000 deaths worldwide. Despite the importance of RSV, there is no licensed vaccine, and no specific form of therapy. This is largely due to the absence of an appropriate animal model for the evaluation of vaccines and therapeutic agents. We inoculated anesthetized infant (4 wk) baboons (Papio anubis) with a human strain of RSV intranasally or intratracheally. Baboons were monitored daily for clinical changes. Anesthetized baboons were intubated at various intervals, and bronchoalveolar lavage (BAL) was performed for viral culture and determination of leukocyte counts. Sham-infected baboons served as controls. Necropsies were performed on infected baboons on days 1, 3, 5, 8, or 13 after inoculation, with pathological analysis and immunohistochemical staining of lung tissues to detect RSV antigen. Infected baboons developed tachypnea and reduced oxygenation peaking from 4 to 8 days after infection and persisting for ≥14 days. Virus was recoverable in BAL fluid up to 8 days following infection. Necropsy revealed intense interstitial pneumonia, sloughing of the bronchiolar epithelium, and obstruction of the bronchiolar lumen with inflammatory cells and sloughed epithelial cells. RSV antigen was identified in bronchiolar and alveolar epithelium. We conclude that RSV-infected infant baboons develop clinical and pathological changes that parallel those observed in human infants with RSV infection. The infant baboon represents a much-needed model for studying the pathogenesis of RSV infection and evaluating antivirals and vaccines.
authors: Oklahoma Baboon Research Resource, Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
authors: James F
authors: JF
authors: Papin
authors: Roman F
authors: RF
authors: Wolf
authors: Stanley D
authors: SD
authors: Kosanke
authors: Justin D
authors: JD
authors: Jenkins
authors: Sara N
authors: SN
authors: Moore
authors: Michael P
authors: MP
authors: Anderson
authors: Robert C
authors: RC
authors: Welliver
mesh_terms: D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001992:Bronchoalveolar Lavage Fluid / Q000821:virology; D004195:Disease Models, Animal; D006801:Humans; D007223:Infant; D008168:Lung / Q000276:immunology / Q000473:pathology; D008992:Monkey Diseases / Q000473:pathology* / Q000503:physiopathology / Q000821:virology; D048530:Papio anubis / Q000821:virology*; D018357:Respiratory Syncytial Virus Infections / Q000473:pathology / Q000503:physiopathology / Q000662:veterinary* / Q000821:virology; D022261:Respiratory Syncytial Virus Vaccines / Q000494:pharmacology; D012136:Respiratory Syncytial Viruses / Q000276:immunology / Q000472:pathogenicity*; D013045:Species Specificity; D014779:Virus Replication
chemical_list: D000914:Antibodies, Viral; D022261:Respiratory Syncytial Virus Vaccines